釓類對比劑蓄積相關報導網頁

  1. FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue.  https://www.fda.gov/Drugs/DrugSafety/ucm559007.htm
  2. ACR Response to the European PRAC Recommendations.  ttps://www.acr.org/About-Us/Media-Center/Press-Releases/2017-Press-Releases/20170404-ACR-Response-to-the-European-PRAC-Recommendations
  3. Contrast Caution: 5 Things Every Radiologist Should Know About Gadolinium. http://www.radiologybusiness.com/topics/care-optimization/contrast-caution-5-things-every-radiologist-should-know-about-gadolinium

  4. Gadolinium-containing contrast agents. PRAC confirms restrictions on the use of linear gadolinium agents. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Gadolinium-containing_contrast_agents/human_referral_prac_000056.jsp&mid=WC0b01ac05805c516f

 

聯絡我們

普樂可醫藥股份有限公司 地址 : 台北市民生東路一段58號11樓 電話 : (02) 2521-0566
傳真 : (02) 2571-0157
p5418173@ms17.hinet.net